Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FHIT | P49789 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 8/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.40 |
| ▸ | NADK | O95544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444131 | 0.87 | ADH1A (0.43) | BCHEADH1AIMPDH2IMPDH1NADK | |
| SCHEMBL24258562 | 0.87 | BCHE (0.42) | FHITBCHEADH1AIMPDH2IMPDH1 | |
| SCHEMBL21264014 | 0.83 | IMPDH2 (0.54) | FHITADH1AIMPDH2ENPP1P2RY11 | |
| SCHEMBL20325291 | 0.80 | P2RY1 (0.52) | FHITBCHEENPP1P2RY11 | |
| SCHEMBL20324638 | 0.80 | P2RY1 (0.52) | FHITBCHEENPP1P2RY11 | |
| SCHEMBL24681007 | 0.77 | BCHE (0.51) | FHITBCHEENPP1P2RY11 | |
| SCHEMBL24258564 | 0.76 | IMPDH2 (0.46) | FHITADH1AIMPDH2IMPDH1NADK | |
| SCHEMBL24258672 | 0.75 | TAS1R3 (0.41) | ADH1AIMPDH2IMPDH1NADK | |
| SCHEMBL21263869 | 0.74 | AHCY (0.43) | FHITADH1AIMPDH2IMPDH1NADK | |
| SCHEMBL21417366 | 0.74 | P2RY1 (0.66) | P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | FHIT 4468/4885BCHE 3073/4885ADH1A 3178/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | FHIT 4468/4885BCHE 3073/4885ADH1A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.